• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

C-C 基序趋化因子 2-C-C 趋化因子受体 2 阻断剂（包括普罗加曼）作为抗癌剂的潜力。

Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.

机构信息

Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.

出版信息

Cancer Sci. 2019 Jul;110(7):2090-2099. doi: 10.1111/cas.14075. Epub 2019 Jun 10.

DOI:10.1111/cas.14075
PMID:31111571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6609805/
Abstract

Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

摘要

炎症在大多数癌症的发生和发展中起着至关重要的作用。趋化因子 C-C 基序趋化因子 2（CCL2）及其受体 C-C 趋化因子受体 2（CCR2）构成了炎症中的一个关键信号轴，最近基于其与癌症进展相关的证据，引起了广泛关注。Propagermanium（3-氧代锗丙酸聚合物）是一种有机锗化合物，在日本用于治疗乙型肝炎，可抑制 CCL2-CCR2 信号通路。本文综述了趋化因子 CCL2-CCR2 轴作为癌症治疗靶点的重要性，包括 Propagermanium 在内的药理学药物在小鼠和人类研究中的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/b5b60b5169b7/CAS-110-2090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/4f01a33e5e64/CAS-110-2090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/8e3aed526ccf/CAS-110-2090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/b5b60b5169b7/CAS-110-2090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/4f01a33e5e64/CAS-110-2090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/8e3aed526ccf/CAS-110-2090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/b5b60b5169b7/CAS-110-2090-g003.jpg

相似文献

1
Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.C-C 基序趋化因子 2-C-C 趋化因子受体 2 阻断剂（包括普罗加曼）作为抗癌剂的潜力。
Cancer Sci. 2019 Jul;110(7):2090-2099. doi: 10.1111/cas.14075. Epub 2019 Jun 10.
2
The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.CCR2抑制剂普罗加比可减轻饮食诱导的胰岛素抵抗、脂肪组织炎症和非酒精性脂肪性肝炎。
PLoS One. 2017 Jan 11;12(1):e0169740. doi: 10.1371/journal.pone.0169740. eCollection 2017.
3
Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?C-C 基序趋化因子配体 2-C-C 趋化因子受体 2 轴是癌症治疗和诊断的有前途的靶点吗？
Int J Mol Sci. 2020 Dec 7;21(23):9328. doi: 10.3390/ijms21239328.
4
An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2.一种抗炎药物，普罗锗烷，可能作用于与单核细胞趋化蛋白-1受体CCR2相关的糖基磷脂酰肌醇锚定蛋白。
J Interferon Cytokine Res. 2001 Jun;21(6):389-98. doi: 10.1089/107999001750277862.
5
Targeting the CCL2-CCR2 signaling axis in cancer metastasis.靶向CCL2-CCR2信号轴以治疗癌症转移。
Oncotarget. 2016 May 10;7(19):28697-710. doi: 10.18632/oncotarget.7376.
6
Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.雌激素通过 PI3K/AKT/NF-κB 信号通路上调 Twist，通过 CCL2-CCR2 轴促进激素依赖性乳腺癌的进展。
Sci Rep. 2018 Jun 22;8(1):9575. doi: 10.1038/s41598-018-27810-6.
7
Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.使用CCL2中和抗体阻断CCL2-CCR2轴是小鼠模型中肝细胞癌的有效治疗方法。
Mol Cancer Ther. 2017 Feb;16(2):312-322. doi: 10.1158/1535-7163.MCT-16-0124. Epub 2016 Dec 15.
8
CCL2-CCR2 Signaling in Disease Pathogenesis.疾病发病机制中的CCL2-CCR2信号传导
Endocr Metab Immune Disord Drug Targets. 2015;15(2):105-18. doi: 10.2174/1871530315666150316120920.
9
Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.CCL2-CCR2 信号轴在癌症中的作用：机制与治疗靶点。
Cell Prolif. 2021 Oct;54(10):e13115. doi: 10.1111/cpr.13115. Epub 2021 Aug 31.
10
Chemokine (C-C Motif) Ligand 2/Chemokine Receptor 2 (CCR2) Axis Blockade to Delay Chondrocyte Hypertrophy as a Therapeutic Strategy for Osteoarthritis.趋化因子（C-C 基序）配体 2/趋化因子受体 2（CCR2）轴抑制软骨细胞肥大作为骨关节炎的治疗策略。
Med Sci Monit. 2021 Dec 8;27:e930053. doi: 10.12659/MSM.930053.

引用本文的文献

1
Azelaic acid attenuates CCL2/CCR2 axis-mediated skin trafficking of acute myeloid leukemia cells through NF-κB/MAPK signaling modulation in keratinocytes.壬二酸通过调节角质形成细胞中的NF-κB/MAPK信号通路，减弱CCL2/CCR2轴介导的急性髓系白血病细胞的皮肤迁移。
BMC Cancer. 2025 Jul 31;25(1):1250. doi: 10.1186/s12885-025-14648-1.
2
Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration.实验性肺纤维化中的分子成像显示，尼达尼布意外地调节了CCR2免疫细胞浸润。
EBioMedicine. 2024 Dec;110:105431. doi: 10.1016/j.ebiom.2024.105431. Epub 2024 Nov 7.
3

本文引用的文献

1
Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.表达因子 XIIIa 的炎症性单核细胞通过纤维蛋白交联促进肺鳞癌。
Nat Commun. 2018 May 18;9(1):1988. doi: 10.1038/s41467-018-04355-w.
2
Targeting both tumour-associated CXCR2 neutrophils and CCR2 macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.靶向肿瘤相关 CXCR2 中性粒细胞和 CCR2 巨噬细胞可破坏髓系细胞募集并改善胰腺导管腺癌的化疗反应。
Gut. 2018 Jun;67(6):1112-1123. doi: 10.1136/gutjnl-2017-313738. Epub 2017 Dec 1.
3
The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.
Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies.
揭示肿瘤相关巨噬细胞在驱动上皮-间质转化中的作用：机制与治疗策略综述
Front Pharmacol. 2024 Sep 2;15:1404687. doi: 10.3389/fphar.2024.1404687. eCollection 2024.
4
Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.解读胶质母细胞瘤：对胶质瘤生物学和治疗策略的基础与新见解
Curr Issues Mol Biol. 2024 Mar 13;46(3):2402-2443. doi: 10.3390/cimb46030153.
5
Current trends and future prospects of drug repositioning in gastrointestinal oncology.胃肠道肿瘤药物重新定位的当前趋势与未来前景
Front Pharmacol. 2024 Jan 4;14:1329244. doi: 10.3389/fphar.2023.1329244. eCollection 2023.
6
EMT-induced immune evasion: connecting the dots from mechanisms to therapy.EMT 诱导的免疫逃逸：从机制到治疗的关联。
Clin Exp Med. 2023 Dec;23(8):4265-4287. doi: 10.1007/s10238-023-01229-4. Epub 2023 Nov 15.
7
The role of germanium in diseases: exploring its important biological effects.锗在疾病中的作用：探索其重要的生物学效应。
J Transl Med. 2023 Nov 8;21(1):795. doi: 10.1186/s12967-023-04643-0.
8
CircHSPB6 Promotes Tumor-Associated Macrophages M2 Polarization and Infiltration to Accelerate Cell Malignant Properties in Lung Adenocarcinoma by CCL2.环状 RNA（circHSPB6）通过 CCL2 促进肿瘤相关巨噬细胞 M2 极化和浸润，从而加速肺腺癌的细胞恶性特征。
Biochem Genet. 2024 Apr;62(2):1379-1395. doi: 10.1007/s10528-023-10482-x. Epub 2023 Aug 23.
9
CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway.CC 趋化因子 2 通过 MEK/ERK/MAP3K19 信号通路促进卵巢癌进展。
Int J Mol Sci. 2023 Jun 26;24(13):10652. doi: 10.3390/ijms241310652.
10
Chemokines as possible therapeutic targets in metastatic melanoma.趋化因子作为转移性黑色素瘤的可能治疗靶点。
Cancer Med. 2023 Jul;12(13):14387-14402. doi: 10.1002/cam4.6055. Epub 2023 May 11.
CCR2抑制剂普罗加比可减轻饮食诱导的胰岛素抵抗、脂肪组织炎症和非酒精性脂肪性肝炎。
PLoS One. 2017 Jan 11;12(1):e0169740. doi: 10.1371/journal.pone.0169740. eCollection 2017.
4
CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice.CCL2/CCR2调节小鼠中HER-2/neu驱动的乳腺癌的肿瘤微环境。
PLoS One. 2016 Nov 7;11(11):e0165595. doi: 10.1371/journal.pone.0165595. eCollection 2016.
5
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.在临界可切除和局部晚期胰腺癌患者中，使用CCR2抑制剂联合FOLFIRINOX靶向肿瘤相关巨噬细胞：一项单中心、开放标签、剂量探索、非随机的1b期试验。
Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.
6
Targeting the CCL2-CCR2 signaling axis in cancer metastasis.靶向CCL2-CCR2信号轴以治疗癌症转移。
Oncotarget. 2016 May 10;7(19):28697-710. doi: 10.18632/oncotarget.7376.
7
CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function.CCL2通过增强多形核骨髓来源的抑制性细胞群及其功能促进结直肠癌发生。
Cell Rep. 2015 Jul 14;12(2):244-57. doi: 10.1016/j.celrep.2015.06.024. Epub 2015 Jul 2.
8
Structural Basis for Polymer Packing and Solvation Properties of the Organogermanium Crystalline Polymer Propagermanium and Its Derivatives.
J Pharm Sci. 2015 Aug;104(8):2482-8. doi: 10.1002/jps.24486. Epub 2015 Jun 2.
9
CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.CCL2 和 CCL5 是雌激素依赖性乳腺癌的新型治疗靶点。
Clin Cancer Res. 2015 Aug 15;21(16):3794-805. doi: 10.1158/1078-0432.CCR-15-0204. Epub 2015 Apr 21.
10
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.癌症免疫治疗中的趋化因子受体特异性抗体：成就与挑战。
Front Immunol. 2015 Jan 30;6:12. doi: 10.3389/fimmu.2015.00012. eCollection 2015.